Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
1.602 Leser
Artikel bewerten:
(2)

Omega Protein Statement on Menhaden Fishery Moratorium

REEDVILLE, VA / ACCESSWIRE / December 19, 2019 / Omega Protein is disappointed in today's decision by the Secretary of Commerce to impose a moratorium on Virginia's menhaden fishery. This is the first time that a moratorium has been placed on a fishery that is not overfished and is healthy by every measure.

The ruling is the result of a requested federal non-compliance review from the Atlantic States Marine Fisheries Commission (ASMFC), following Virginia's decision not to adopt the Commission's fishery management provision further lowering the cap on menhaden reduction harvests in the Chesapeake Bay.

The Company maintains that the 41 percent decrease in the Bay cap has never been based on science, and is unnecessary for the conservation of the menhaden fishery. Since it was first implemented in 2006, no evidence has been produced showing that it is necessary, or that localized depletion of menhaden has ever occurred in the Chesapeake Bay.

The ASMFC has previously acknowledged that there is no evidence supporting the need for a Bay cap. When Virginia initially appealed the latest reduction of the cap, the Commission's leadership stated in its response that its menhaden Fishery Management Plan contained "no evidence to suggest the Bay Cap is necessary to protect the Bay as a nursery for other species." When it was first implemented in 2008, the then-director of the ASMFC testified before a Congressional committee that there "was not a science basis for the cap."

Despite this, the Commission reduced the Bay cap three times over the last 13 years, most recently to 51,000 metric tons, at the expense of the hard-working members of the menhaden fishery. These reductions have been made despite ample evidence that the fishery is sustainable. In fact, the fishery was recently certified as sustainable by the Marine Stewardship Council; the Commission itself has raised the coastwide quota 3 times since 2015, indicating that there is a broad consensus about the health of the fishery.

Omega Protein has historically supported the Commission process and respected the decisions of the ASMFC. However, the company remains firm in its belief that fishery management should be based on science, not on politics.

In response to this decision, Omega Protein will work with both the ASMFC and the Commonwealth of Virginia to lift the moratorium and bring the fishery back into compliance. The Company looks forward to working with the Commission in the coming months as we move toward ecosystem-based measures, and will continue to support science-based fishery management and a healthy menhaden fishery.

About Omega Protein

Omega Protein Corporation is a century old nutritional product company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of foods, dietary supplements and animal feeds. Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined specialty oils, specialty proteins products and nutraceuticals. Omega Protein is a division of Cooke Inc., a family owned fishery company based in New Brunswick, Canada.

The Company operates seven manufacturing facilities located in the United States, Canada and Europe. The Company also has a long-term supply contract with Ocean Harvesters, which owns 30 vessels which harvest menhaden, a fish abundantly found off the coasts of the Atlantic Ocean and Gulf of Mexico. The Company's website is www.omegaprotein.com.

All fishing vessels formerly owned by Omega Protein are owned and operated by Ocean Harvesters, an independent company.

Press Contact

Ben Landry
Director of Public Affairs, Omega Protein
(713) 940-6183
blandry@omegaprotein.com

SOURCE: Omega Protein Corporation



View source version on accesswire.com:
https://www.accesswire.com/570801/Omega-Protein-Statement-on-Menhaden-Fishery-Moratorium

© 2019 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.